lyj19721101 2015-07-16 15:12 IP:马鞍山
罕见癌症研究基金会(RCRF),致力于通过战略投资和创新合作进行基础治疗罕见的癌症,和美国文化募捐组织(ATCC),世界上最大的非营利性细胞株库,建立神经内分泌肿瘤细胞株收集目录。肠道良性肿瘤和胰腺神经内分泌肿瘤(PNET)需求一种新疗法的研究和发展,即在体内原发性肿瘤中建立新的细胞株。 为了刺激发展新的良性肿瘤和PNET细胞系,该基金会是高兴地宣布第二次开放竞争十个人奖项:开发人员的第一个新的细胞系在每个疾病(肠道良性肿瘤和PNET)将获得100000美元,开发者的第二,第三,第四,第五个新细胞系在每个疾病将会收到50000美元。原文如下:https://www.innocentive.com/ar/challenge/9933756 The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery. Source: InnoCentive Challenge ID: 9933756 Challenge Overview This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use. To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual   [更多]
悬赏:
悬赏
¥600000.00
载入中...
18246030621 2015-10-15 10:10 IP:长春
招募急性痛风性关节炎志愿者 招募概述: 如果您是急性痛风性关节炎患者,符合以下条件就可以报名参加虎贞痛风胶囊的临床研究。虎贞痛风胶囊由广东一力集团制药有限公司/广州暨南生物医药研究开发基地有限公司研制并提供的,并于2008年经国家食品药品监督管理局批准进行临床研究,临床试验批件号:2008L02043。其具有清热利湿,化瘀利浊,滋补肝肾的功效。主治急性痛风性关节炎(湿热蕴结证),症见:关节红肿热痛,伴有发热,汗出不解,口渴喜饮,心烦不安,小便黄及痛风病见上述症候者。此研究由中国中医科学院广安门医院等15家医院共同参与。 如果您愿意参加本项研究并通过筛选符合条件,我们将为您提供3天的免费治疗并免费进行相关检查(包含:体格检查、血常规、尿常规、便常规、肝肾功、心电图、血尿酸、类风湿因子、血沉、C反应蛋白和抗链球菌溶血素‘O’)。 入选条件: 1.符合急性痛风性关节炎诊断标准,且辨证为湿热蕴结证。 2.急性发作在48小时之内,本次发作未用过治疗药(包括秋水仙碱、非甾类抗炎药及激素等)者。 3.VAS评分≥4分。 4.年龄18-65岁。 5.签署知情同意书。 您一旦参加本试验将获得较全面的检查和试验药物治疗,并将得到医生的全面跟踪随访。 如您符合纳入标准,并有意参加本研究项目,请到辽宁中医药大学第二附属医院住院部A楼三楼糖尿病科咨询 。 地址:沈阳市皇姑区黄河北大街60号 联系方式:江红主任:138 4008 4568 马尧医生:139 4046 6290   [更多]
悬赏:
悬赏
¥0.00
载入中...
richard16 2016-05-13 08:37 IP:重庆
理论分析一种材料,能有明显区分其与丙酮或水(潮湿)的物理作用。如膨胀,收缩,卷曲,等等。此材料不限于纤维,膜剂或织物。 “请于2016年5月23日之前将稿件上传到:https://www.innocentive.com/ar/challenge/9933858 “ Challenge Overview Many materials (usually polymers) change shape when exposed to acetone (ketones in general) but also have a large affinity for moisture as well. It would be very difficult to attribute physical changes to acetone or water if both were present. The Seeker is looking for materials and associated processes that produce an observable physical change to the substrate upon exposure to acetone. The material should not have the same effect when exposed to moisture so the two can be differentiated. The effect should be reversible and the rate of absorb/desorb should be similar. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rightsto the solution. However, the Seeker will be willing to consider a licensing agreement for a partial award if exclusive IP cannot be transferred by the Solver. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on May 23, 2016. Late submissions will not be considered.   [更多]
悬赏:
悬赏
¥0.00
载入中...
tommorow 2016-07-17 15:15 IP:临沂
专利申请号:201620283879.X,实用新型,处于授权未交费状态。   [更多]
悬赏:
悬赏
¥3750000.00
载入中...
霍扬 2016-08-23 14:39 IP:北京
1、化学药3/4类均可,不考虑中药; 2、提供该项目基础信息、基本市场信息、专利信息等; 3、有一定的优势和发展前景; 4、限于口服制剂(固体和液体)、吸入粉。 5、有意向的可进行合作开发,或者由我公司出资委托你方进行开发。   [更多]
悬赏:
悬赏
¥100.00
载入中...
woailuozhiyu 2016-11-28 14:57 IP:北京
求购“Solifenacin+succinate”《 EP9.0 》的药典标准一份   [更多]
悬赏:
悬赏
¥1.00
载入中...
mayankw 2017-05-26 08:56 IP:北京
具体要求:控股权转让。 剂型:片剂、胶囊、口服液、软膏、冻干粉、小水针。 1、必须是有效的生产批文。 2、直接提供批文所有者的联系方式。 3、必须是药智网转让数据库中没有的信息。   [更多]
悬赏:
悬赏
¥150.00
载入中...
时间就是生命 2018-03-26 01:21 IP:未知
标题:请人查一篇关于抗癌的文献! 需求名称:自定义 价格预算:300元 详细要求: 需求时间:请在2018年7月5号提交 交稿方式:请将文献直接打包在药智网交稿就可以了   [更多]
悬赏:
悬赏
¥60.00
载入中...
合子 2019-04-12 11:31 IP:上海
求助亲核取代法制备的fluorodopa (18f) injection BP2019 及EP9.7各一份   [更多]
悬赏:
悬赏
¥80.00
载入中...
njzc1234 2019-11-07 15:58 IP:南京
盐酸纳呋拉啡或盐酸纳呋拉啡口崩片的信息。   [更多]
悬赏:
悬赏
¥1600.00
载入中...
发布需求,坐等药智客上门
  • 安全可靠,先验收再正式付款
  • 性价比超高,节省一半费用
  • 80%的需求得到了圆满解决
立即发布需求

推荐任务